logo-loader
viewZelira Therapeutics Ltd

Zelda enters rapidly-growing German market with product commercialisation strategy

Zelda Therapeutics Ltd (ASX:ZLD) founder and executive chairman Harry Karelis updates Proactive Investors on the cannabis company’s progress with clinical trials as well as its recent entry into the German market.
 
Zelda has entered a distribution and manufacturing strategic partnership with German medicinal cannabis group HAPA Medical.
 
As per the deal, HAPA will have first rights to distribute and/or manufacture Zelda’s clinically validated formulations into the rapidly growing German market.
 
With a population of 83 million people, Germany is estimated to have the potential to become the world’s largest single medical cannabis market.

Quick facts: Zelira Therapeutics Ltd

Price: 0.06 AUD

ASX:ZLD
Market: ASX
Market Cap: $57.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read